Player Avatar zzlangerhans (99.85) Submitted: 4/26/2011 7:19:34 PM : Outperform Start Price: $3.17 RPTP Score: +82.34

Raptor Pharmaceuticals ... I'm not a fan. I've made my reasons for that clear before. But today the share price dipped to a new six-month low and I think it will go up from here in the short term. Traders may have become bored with the Raptor story after they announced that due to a mathematical error, they would have to enroll more patients in their phase III study of DR Cysteamine in cystinosis. That slip of the calculator also resulted in a delay of topline results to the current quarter. But goof-up or not, the trial has a fairly good chance of yielding positive results given the narrow indication it is designed for. I expect DR Cysteamine to be as effective as the standard of care Cystagon, and maybe they'll actually show a significant reduction in side effects.

Efficacy in nephropathc cystinosis is a long way from efficacy in the uncharted territory of Huntington's disease and NASH. As I do with other companies that promote a single drug across multiple indications, I'll be giving this a wide berth after the phase III trial results bump them up.

Featured Broker Partners